The FDA has approved the atypical antipsychotic, Fanapt (iloperidone, from Vanda Pharmaceuticals), a mixed dopamine D2/serotonin 5HT2A receptor antagonist, for the acute treatment of schizophrenia in adult patients. This approval was based on data from two Phase III, placebo-controlled clinical studies comparing Fanapt to placebo and active control in more than 3,000 patients with schizophrenia. Fanapt was shown to be superior to placebo in controlling symptoms of schizophrenia based on the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale (BPRS) total score.
Fanapt is expected to be available later this year.
For more information call (240) 599-4500 or visit www.vandapharma.com.